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Impact of left ventricular hypertrophy on survival in end-stage renal
disease. We examined the prognostic significance of left ventricular
hypertrophy determined by echocardiography in a cohort beginning
renal replacement therapy. No patient had hemodynamically significant
valvular disease or echocardiographic signs of obstructive cardiomyop-
athy. Using the Cox proportional hazards model, left ventricular
hypertrophy was significantly associated with survival. The relative
risk, based on comparison of upper and lower quintiles of left ventric-
ular mass index, was 3.7 (95% confidence intervals, 1.6 to 8.3) for
all-cause mortality and 3.7 (95% confidence intervals, 1.2 to 11.1) for
cardiac mortality. The independent risk, adjusted for age, known
coronary artery disease, diabetes, level of systolic blood pressure, and
treatment (dialysis or transplantation), was 2.9 (95% confidence inter-
vals, 1.3 to 6.9) for all-cause mortality and 2.7 (95% confidence
intervals, 0.9 to 8.2) for cardiac mortality. Therefore, left ventricular
hypertrophy appears to be an important, independent, determinant of
survival in patients receiving therapy for end-stage renal failure.
Left ventricular hypertrophy is an important marker of risk
for death and other adverse events in patients with hyperten-
sion [1, 2] as well as in otherwise normal people [3—5]. Although
the mechanisms have not been established definitively, asymp-
tomatic ventricular arrhythmias are prevalent [6, 7], as are
abnormalities of vasodilator reserve [8, 91 and abnormalities of
the coronary microcirculation [10].
Cardiovascular events remain the major cause of mortality
and morbidity in patients with end-stage renal disease [11]. We
have reported a high prevalence of left ventricular hypertrophy
determined by echocardiography in patients treated by chronic
ambulatory peritoneal dialysis; in that study, left ventricular
hypertrophy seemed to be strongly associated with mortality
during a short follow-up period [121. The present study was thus
designed to evaluate the independent prognostic significance of
left ventricular hypertrophy in a larger population with end-
stage renal disease treated by all modalities (hemodialysis,
intermittent and continuous peritoneal dialysis, and transplan-
tation).
Methods
The Royal Victoria Hospital is a tertiary referral institution
affiliated with McGill University which offers all forms of renal
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replacement therapy with the exception of home hemodialysis.
Since 1983 a prospective protocol has existed to determine the
characteristics of patients receiving treatment for end-stage
renal disease. All patients beginning therapy between January
1983 and August 1987 were screened for inclusion in the study.
Patients were excluded if they had hemodynamically significant
valvular disease, if they had begun dialysis at another institu-
tion, if they were restarting after failed transplantation, if they
had known pre-existing malignant disease, or if they had acute
renal failure and either died or recovered renal function. Pa-
tients with acute renal failure who did not recover renal
function but survived and required maintenance replacement
therapy were included. Patients beginning treatment here who
transferred to other institutions were followed as to vital status.
Aside from left ventricular hypertrophy, other potentially
important prognostic variables studied were age, sex, type and
duration of underlying kidney disease, duration of hypertension
or diabetes mellitus, level of systolic and diastolic blood pres-
sure, definite and suspected coronary artery disease, smoking
history, and serum calcium, phosphate, and parathyroid hor-
mone levels. Myocardial infarction was considered 'Definite' if
the electrocardiogram revealed abnormal Q-waves or if there
was regional wall motion abnormality on the two-dimensional
echocardiogram with appropriate electrocardiographic chang-
es. Electrocardiographic left ventricular hypertrophy was based
on Romhilt-Estes Criteria [13].
Echocardiography
All studies were performed using an ATL-600 apparatus
(Advanced Technology Laboratories, Bothell, Washington,
USA), Two-dimensional imaging was used to guide the M-mode
beam. Evaluation of valves included pulsed and continuous
wave Doppler. All studies were reported by one of two observ-
ers according to American Society for Echocardiography crite-
ria [14]. Left Ventricular Mass Index (LVMI) was determined
according to the method of Devereux and Reichek [15].
Outcome
Vital status was established by a physician for all subjects.
Cardiac death was defined according to criteria based on those
used in the Lipid Research Clinics trial [16] as sudden (unex-
pected) death, death associated with a definite myocardial
ischemic event, or death in heart failure (refractory to ultrafil-
tration).
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Statistics
Analysis was performed using SAS (SAS Institute Inc., Cary,
North Carolina, USA, 1985) and BMDP (University of Califor-
nia, 1983) statistical software. The Cox proportional hazards
model was used to estimate the survival function, with trans-
plantation as a time-dependent covariate [17]. Confidence inter-
vals for rate ratios were test-based [181. Survival curves were
constructed according the method of Kaplan and Meier [191.
Results
Of 390 patients receiving renal replacement therapy during
the study period, 119 met the entry criteria. The reasons for
exclusion of the remaining patients are shown in Table 1. Of
those eligible, 91 patients (77%) underwent the intended echo-
cardiographic study either prior to or within the first two
months of beginning replacement therapy (median: 51 days
pre-starting). Twenty-two patients (19%) were studied for the
first time later in the course of dialysis while six patients (4%)
died within two months of beginning therapy without having an
echocardiographic study.
The 91 patients who had an early echocardiographic exami-
nation were studied in the survival analysis (Fig. 1). Their
clinical characteristics are given in Table 2. All patients with
prior definite myocardial infarction or coronary bypass grafting
had subsequent angina. No patient had asymmetric septal
hypertrophy, systolic anterior motion of the mitral valve, or
midsystolic aortic valve closure at echocardiography. Median
follow-up was 576 days (range: 2 to 1839) from the commence-
ment of replacement therapy.
Determinants of mortality: Crude associations
Based on a comparison of uppermost (>166 gIm2) and low-
ermost (<83 g/m2) quintiles of left ventricular mass index, the
risk ratio (relative risk) for left ventricular hypertrophy was 3.7
for both all-cause mortality and cardiac mortality (Tables 3 and
4). The risk ratio for end-systolic dimension for all-cause
390 Screened
Table 1. Cohort selection Table 2. Clinical characteristics (all values are expressed as
mean sn)
271 Excluded
Ill Acute renal failure
100 Began pre-1983
10 Prior transplantation
28 Began elsewhere
No. patients
Age: mean
range
Sex M/F
(% Male)
91
55 15
20—87
55/36
60
17 Pre-existing malignancy
4 Valve disease: 1 Mixed mitral valve disease
1 Mitral valve replacement
2 Aortic stenosis
1 Chart not available
Kidney disease
Glomerulonephritis
Diabetes
Nephrosclerosis
Pyelonephritis
25 (27%)
21(23%)
15 (16%)
13 (14%)
119 Eligible Other 17 (18%)
91 Early echocardiography
22 Late echocardiography only Definite myocardial infarction 10 (11%)
6 No echocardiography Angina
Hypertension
Systolic blood pressure mm Hg
Diastolic blood pressure mm Hg
Urea mmol//iter
Hemoglobin gluIer
Transplanted during follow-up
Echocardiography
LVMI g/m2
Range
LV End-systole mm
Range
LV End-diastole mm
Range
LV Posterior wall mm
Range
27 (30%)
67 (73%)
152 24
86 11
35 14
90 25
18 (20%)
121 32
65—198
34 7
20—60
51 7
35—72
11.4 1
9—15
100
80
60
40
20
0
Fig. 1. Cumulative survival according to echocardiographic left ven-
tricular hypertrophy defined as LVMI > 125 glm2. This cutpoint
corresponds to the 95th centile of 2 normal populations reported by
Casale et al [11.
a Nephrosclerosis includes hypertension but not diabetes; Pyelone-
125 gIm2 phritis includes analgesic nephropathy.
Abbreviations are: LVMI, left ventricular mass index; LV, left
ventricle.
1 2 3 4 5
Time, years
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Table 3. Crude associations: All-cause mortality
95%
Confidence
Variable Coefficient Pa
.Relative
riskb
interval
Lower Upper
Age years 0,0785 <0.0002 26.6 7.9 89.6
Male sex 0.1049 0.77 1.1 0.8 1.4
LVMI g/m2 0.0156 0.0026 3.7 1.6 8.3
ESD mm 0.0664 0.14 2.6 0.9 7.4
Syst BP mm Hg 0.0094 0.36 1.8 0.8 4.3
Hypertension 0.4569 0.68 1.6 0.6 4.3
Angina 1.5820 <0.0002 4.9 2.4 9.8
Definite MI 1.1616 0.0320 3.2 1.6 6.5
Diabetes 0.8400 0.0234 2.3 1.2 4.5
Transplant —2.53 0.0036 0.08 0.01 0.6
Abbreviations are: LVMI, left ventricular mass index; ESD, end-
systolic dimension; Syst BP, systolic blood pressure; MI, myocardial
infarction.
a pvalues are two sidedb For continuous variables, relative risk estimates are based on
comparison of top and bottom quintiles.
Table 4. Crude associations: Cardiac mortality
95% Confidence
Relative interval
Variable Coefficient Pa riskb Lower Upper
Age years 0.0653 0.0004 15.3 3.3 70.5
Male sex 0.2730 0.58 1.3 0.6 3.3
LVMI g/m2 0.0157 0.0354 3.7 1.2 11.1
ESDmm 0.0960 0.0808 3.8 1.1 13.9
Syst BP mm Hg 0.0075 0.870 1.6 0.5 5.2
Hypertension 1.6272 0.158 5.1 0.7 38.4
Diabetes 1.2753 0.0084 3.6 1.4 9.2
Angina 2.2167 <0.0002 9.2 3.4 24.7
Definite MI 1.7170 0.0032 5.6 1.9 16.3
TransplanP
Abbreviations are: LVMI, left ventricular mass index; ESD, end-
systolic dimension; Syst BP, systolic blood pressure; ML, myocardial
infarction.
a pvalues are two-sided
b For continuous variables, relative risk estimates are based on
comparison of top and bottom quintiles.
No transplanted patient suffered a cardiac death. The coefficient is
thus inestimable.
mortality was 2.6 (one-sided P 0.07), and for cardiac mortal-
ity, 3.8 (one-sided P = 0.04). Age (uppermost quintile: >76
years; lowermost quintile: <35 years) was a very powerful
predictor, with an estimated relative risk of 26 for all-cause and
15 for cardiac mortality. The relative risk associated with
angina was 4.9 for all-cause and 9.2 for cardiac mortality, and
with definite myocardial infarction 3.2 (all-cause) and 5.6 (car-
diac). Diabetes was more strongly associated with cardiac
(relative risk 3.6) than with all-cause mortality (relative risk
2.3). Neither the diagnosis of hypertension nor the actual level
of systolic blood pressure were associated with all-cause mor-
tality, although there was a trend to greater cardiac mortality in
hypertensives (relative risk 5.1, one-sided P = 0.07). Neither
cause (other than diabetes) nor duration of known kidney
disease were significantly associated with mortality, nor were
blood urea, hemoglobin, calcium, phosphate, alkaline phos-
phatase, parathyroid hormone levels, or smoking status. Only
Table 5. Adjusted associations: All-cause mortality
Variable Coefficient Pa
Relative
riskb
95% Confidence
interval
Lower Upper
Age 0.0594 0.0002 12.0 3.1 46.4
LVMI 0.0126 00132 2.9 1.3 6.7
Hypertension 0.2512 0.6170 1.3 0.5 3.7
Angina 0.6958 0.0768 2.0 0.9 4.3
Diabetes 0.5672 0.1164 1.8 0.9 3.8
Transplant —1.3317 0.2150 0.3 0.03 2.2
Abbreviation is: LVMI, left ventricular mass index.
a pvalues are two-sided
For continuous variables, relative risk estimates are based on
comparison of top and bottom quintiles.
Table 6. Adjusted associations: Cardiac mortality
Variable Coefficient Pa
Relative
risk1'
95% Confidence
interval
Lower Upper
Age 0.0417 0.0384 5.7 0.8 29.9
LVMI 0.0119 0.0784 2.7 0.9 8.2
Hypertension 1.3243 0.2076 3.8 0.5 30.2
Angina 1.6223 0.0034 5.1 1.7 15.2
Diabetes 0.9827 0.0488 2.7 1.0 7.3
Abbreviation is: LVMI, left ventricular mass index.
a pvalues are two sidedb For continuous variables, relative risk estimates are based on
comparison of top and bottom quintiles.
one of 18 patients transplanted during the follow-up period died,
the cause being noncardiac. The relative risk with transplanta-
tion was thus inestimable for cardiac mortality, while for
all-cause mortality it was 0.08 (12 to 1 against).
Multivariate analysis
The relationship between left ventricular mass index and
all-cause mortality persisted after adjustment for age, hyperten-
sion, angina, diabetes and transplantation (adjusted relative
risk: 2.9, Tables 5 and 6). Transplantation was not included in
the analysis of cardiac mortality, where the adjusted relative
risk for left ventricular mass index was 2.7 (one-sided P = 0.04).
Components of left ventricular mass index
The prognostic effects of wall thickness and end-diastolic
cavity dimension were examined in a limited model adjusting
for the other. For both all-cause mortality and cardiac mortal-
ity, the risk associated with posterior wall thickness was
independent of cavity dimension (Table 7).
Thickness versus end-systolic dilatation
A further model examined the adjusted effects of posterior
wall thickness and end-systolic cavity dimension. Both wall
thickness (risk ratio for all-cause mortality 2.6, P =0.0037) and
cavity dilatation at end-systole (risk ratio for all-cause mortality
3.2, P = 0.012) exerted important prognostic effects indepen-
dent of each other.
Silberberg et a!: Left ventricular hypertrophy and survival 289
Table 7. Components of LVMI
95%
Confidence
Variable Coefficient pa
.Relative
risk"
interval
Lower Upper
All-cause mortality
PW thickness 0.2581 0.0272 2.2 1.1 4.4
LV diastole 0.0328 0.0749 1.8 0.8 4.0
Cardiac mortality
PW thickness 0.2770 0.0392 2.3 0.9 5.8
LV diastole 0.0301 0.1635 1.7 0.6 4.9
Abbreviations are: PW, posterior wall; LV left ventricle.
a P values are two-sided
b Relative risk estimates are based on comparison of top and bottom
quintiles.
Patients who did not have early echocardiography
The 22 patients who were studied for the first time later in the
course of replacement therapy were of similar clinical charac-
teristics at entry to those who were included in the main
survival analysis. These 22 patients were examined separately
in an analysis of survival from the time of echocardiography. In
this small population the relative risk of mortality associated
with left ventricular mass index (uppermost vs. lowermost
quintile) was 2.5 (one-sided P = 0.11). Four of the six patients
who died before echocardiography could be performed had
electrocardiographic left ventricular hypertrophy.
Discussion
We have found left ventricular hypertrophy, quantitated by
echocardiography and expressed as left ventricular mass index,
to be an important determinant of outcome in patients with
end-stage renal disease. The effect was strong and persisted
after adjustment for associated known prognostic factors. The
prognostic importance of left ventricular hypertrophy evident in
the present study is consistent with findings in patients with
hypertension [1, 2], in apparently normal persons [3—5], and in
trained athletes [20]. Ventricular arrhythmias, probably re-
flecting subendocardial ischemia due to abnormal vasodilator
reserve [8, 9] or structural changes in the coronary microcircu-
lation [10] appear to be the most likely mechanism of increased
risk for death, both unexpected and associated with intercur-
rent acute illness.
The factors for which we adjusted included age, diabetes
mellitus, blood pressure, and coronary disease. Since coronary
angiography was not part of our routine evaluation, we will
necessarily have misclassified some patients. We chose to use
angina rather than definite myocardial infarction as our marker
for coronary disease in order to maximize sensitivity. Angina
may occur in left ventricular hypertrophy without coronary
artery disease, but the effect of this would be to reduce rather
than enhance the apparent hypertrophy/survival relationship.
Given the reported high prevalence of coronary disease in
patients with end-stage renal disease [21] and the possibly
accelerated atherosclerosis in patients maintained on hemodi-
alysis [22], we believe coronary artery disease to be the most
important factor in determining survival in these patients.
However, examining the effect of left ventricular hypertrophy
while adjusting for suspected coronary artery disease, we found
important independent effects. Indeed, it is likely that hyper-
trophy magnifies the impact of associated coronary artery
disease in these patients. The importance of 'parallel' or 'con-
centric' hypertrophy manifest as wall thickening [23] versus
that secondary to cavity dilatation (measured at both end-
diastole and end-systole) was evident when the reduced models
were examined. Posterior wall thickness and end-systolic di-
mension, adjusted for the other, predicted outcome equally
well, with similar relative risks. Of interest, end-systolic vol-
ume, which reflects ventricular systolic performance, has re-
cently been suggested as the best predictor of outcome follow-
ing myocardial infarction [24].
A strength of our study is that we identified all patients
receiving dialysis during the study period, and follow-up was
complete for all patients meeting the entry criteria. We were
less successful in achieving echocardiographic studies at the
intended time since only 77% of our patients were studied at the
initiation of dialysis. The findings in the remaining patients,
however, supported the importance of left ventricular hyper-
trophy in determining outcome.
While echocardiography is unquestionably the best clinical
method available to estimate left ventricular mass, its limits
must not be overlooked. The method requires accurate mea-
surement of the thickness of the left ventricular wall and the
diameter of the left ventricular cavity. From this left ventricular
volume is calculated and the estimate of left ventricular mass
depends on geometric assumptions involved in these calcula-
tions and the assumption of uniform wall thickness. Thus left
ventricular mass is a function of left ventricular thickness and
left ventricular volume, and measurement of wall thickness
alone would incompletely represent left ventricular mass. It
must also be appreciated that left ventricular mass is a compos-
ite of all the tissue elements within the heart. Thus Mall et al
[25] have demonstrated that the increase in left ventricular mass
documented in hypertensive uremic animals correlated, in fact,
better with increased interstitial tissue than with changes in
myocyte size.
The results of this study establish the need to understand
more precisely the determinants of left ventricular hypertrophy
in end-stage renal disease. Hypertension, the presence of an
arteriovenous fistula and anemia must all be considered as
potentially important contributors. Anemia may be of particular
importance since this complication of end-stage renal disease
can now be treated with recombinant erythropoietin. However,
whether left ventricular hypertrophy will regress with such
therapy and whether regression of left ventricular hypertrophy
would improve outcome in end-stage renal disease remains to
be established.
Reprint requests to Dr. A.D. Sniderman, Cardiology Division,
M4.76, Royal Victoria Hospital, Montreal, Quebec, Canada H3A IAI.
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